ABBISKO-B (02256) affiliate Glory Pharmaceuticals has completed the first dose of patient in the Phase 1 clinical trial of the innovative PRMT5*MTA inhibitor ABSK131.

23/07/2025

Hoyu Group B (02256) announces that its subsidiary, Shanghai Hoyu Biomedical Technology Co., Ltd. (Hoyu Medical...

ABBISKO-B (02256) announced that its subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Medicine) announced that its research-based innovative PRMT5*MTA inhibitor ABSK131 has completed the first patient dosing in a phase 1 clinical trial in patients with MTAP-deficient advanced/metastatic solid tumors. In March 2025, ABSK131 received IND approval from the China National Medical Products Administration Drug Evaluation Center. In December 2024, ABSK131 received IND approval from the US Food and Drug Administration.

LEGENDARY EDU (08195) has submitted a formal application to the Stock Exchange for the proposed transfer to a main board listing.

DL HOLDINGS GP(01709): Independent non-executive director Liu Chun has been appointed as a member of the Nomination Committee.

CITIC SEC increased its holdings in Aluminum Corporation Of China (02600) by 6.524 million shares, with each share priced at approximately 6.18 Hong Kong dollars.

LEGENDARY EDU (08195) has submitted a formal application to the Stock Exchange for the proposed transfer to a main board listing.

DL HOLDINGS GP(01709): Independent non-executive director Liu Chun has been appointed as a member of the Nomination Committee.

CITIC SEC increased its holdings in Aluminum Corporation Of China (02600) by 6.524 million shares, with each share priced at approximately 6.18 Hong Kong dollars.